Study of antibiotic-resistant gut bacteria in ICU patients
Part of Infections clinical trials.
This study looks at whether patients in the intensive care unit (ICU) carry certain hard-to-treat bacteria (carbapenem-resistant enterobacteriaceae, or CRE) in their gut. By finding out how common this is, doctors can better protect patients from infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You are expected to stay in the ICU for at least 48 hours.
- You must be willing to provide samples such as stool or rectal swabs for testing.
- No other strict medical conditions are required — the study is open to a wide range of ICU patients.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at factors that make some hospitalized children in the pediatric intensive care unit (PICU) develop or carry germs called carbapenem-resistant Enterobacteriaceae. It aims to understand who is at higher risk and why, which may help prevent infections in the future.
This study looks at how resistant bacteria (germs that are hard to treat) spread in the intensive care unit. It tests whether the amount of bacteria you carry relates to contamination in your room and transmission to others.
This study looks at whether a simple rectal swab test can help predict the risk of developing infections that are resistant to common antibiotics. It focuses on patients in the intensive care unit (ICU) who have already had this swab done as part of their care.
This study looks at bacteria (including antibiotic-resistant germs) present when you are admitted to a hospital. It may help doctors understand how often these germs are carried and how to respond early to prevent spread.
This study looks at how bacteria in the lungs react to antibiotics. By joining, you help doctors understand which antibiotics work best for serious lung infections in the ICU.
This study looks at patients who have severe infections caused by carbapenem-resistant Enterobacterales (CRE), which are bacteria that are hard to treat because they resist many antibiotics. It will examine the germs and how patients respond to newer antibiotics that are specifically used for these tough infections.
Hear when a new Rate of Carbapenemase Intestinal Carrier Inside ICU trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.